References
- Allen L, Dockrell DH, Pattery T, Lee DG, Cornelis P, Hellewell PG, Whyte MK. Pyocyanin production by Pseudomonas aeruginosa induces neutrophil apoptosis and impairs neutrophil-mediated host defenses in vivo. J Immunol. 2005 Mar 15;174(6):3643–3649. https://doi.org/10.4049/jimmunol.174.6.3643
- Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014 Aug;71(3):292–301. https://doi.org/10.1111/2049-632X.12125
- Bernabeu-Wittel M, Pichardo C, García-Curiel A, Pachón-Ibáñez ME, Ibáñez-Martínez J, Jiménez-Mejías ME, Pachón J. Pharmacokinetic/pharmacodynamic assessment of the in vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005;11:319–325. https://doi.org/10.1111/j.1469-0691.2005.01095.x
- Byrne JM, Waack U, Weinstein EA, Joshi A, Shurland SM, Iarikov D, Bulitta JB, Diep BA, Guina T, Hope WW, et al. FDA Public Workshop Summary: advancing animal models for antibacterial drug development. Antimicrob Agents Chemother. 2020 Dec 16;65(1): e01983-20. https://doi.org/10.1128/AAC.01983-20
- Crandon JL, Kim A, Nicolau DP. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother. 2009 Oct;64(4):837–839. https://doi.org/10.1093/jac/dkp301
- Eveillard M, Soltner C, Kempf M, Saint-André JP, Lemarié C, Randrianarivelo C, Seifert H, Wolff M, Joly-Guillou ML. The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia. J Infect. 2010 Feb;60(2):154–161. https://doi.org/10.1016/j.jinf.2009.09.004
- Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006 Mar 1;42(5):692–699. https://doi.org/10.1086/500202
- García-Patiño MG, García-Contreras R, Licona-Limón P. The immune response against Acinetobacter baumannii, an emerging pathogen in nosocomial infections. Front Immunol. 2017 Apr 12;8:441. https://doi.org/10.3389/fimmu.2017.00441
- Geisinger E, Isberg RR. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 2015 Feb 13;11(2):e1004691. https://doi.org/10.1371/journal.ppat.1004691
- Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013 Apr;67(3): 159–173. https://doi.org/10.1111/2049-632X.12033
- Gellings PS, Wilkins AA, Morici LA. Recent advances in the pursuit of an effective Acinetobacter baumannii vaccine. Pathogens. 2020 Dec 19;9(12):1066. https://doi.org/10.3390/pathogens9121066
- Gong L, Cumpian AM, Caetano MS, Ochoa CE, De la Garza MM, Lapid DJ, Mirabolfathinejad SG, Dickey BF, Zhou Q, Moghaddam SJ. Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer. 2013 Dec 9; 12(1):154. https://doi.org/10.1186/1476-4598-12-154
- Harris G, Kuo Lee R, Lam CK, Kanzaki G, Patel GB, Xu HH, Chen W. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother. 2013 Aug;57(8):3601–3613. https://doi.org/10.1128/AAC.00944-13
- Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, Sayood K, Iwen PC, Skaar EP, Dunman PM. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun. 2010 May;78(5):1952–1962. https://doi.org/10.1128/IAI.00889-09
- Joly-Guillou ML, Wolff M, Farinotti R, Bryskier A, Carbon C. In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother. 2000 Nov;46(5):827–830. https://doi.org/10.1093/jac/46.5.827
- Kamath AB, Alt J, Debbabi H, Taylor C, Behar SM. The major histocompatibility complex haplotype affects T-cell recognition of mycobacterial antigens but not resistance to Mycobacterium tuberculosis in C3H mice. Infect Immun. 2004 Dec;72(12):6790–6798. https://doi.org/10.1128/IAI.72.12.6790-6798.2004
- Kamoshida G, Kikuchi-Ueda T, Nishida S, Tansho-Nagakawa S, Ubagai T, Ono Y. Pathogenic bacterium Acinetobacter baumannii inhibits the formation of neutrophil extracellular traps by suppressing neutrophil adhesion. Front Immunol. 2018 Feb 7;9:178. https://doi.org/10.3389/fimmu.2018.00178
- Kamoshida G, Tansho-Nagakawa S, Kikuchi-Ueda T, Nakano R, Hikosaka K, Nishida S, Ubagai T, Higashi S, Ono Y. A novel bacterial transport mechanism of Acinetobacter baumannii via activated human neutrophils through interleukin-8. J Leukoc Biol. 2016 Dec; 100(6):1405–1412. https://doi.org/10.1189/jlb.4AB0116-023RR
- Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012 Feb;39(2):105–114. https://doi.org/10.1016/j.ijantimicag.2011.10.004
- Kim CH, Kim DJ, Lee SJ, Jeong YJ, Kang MJ, Lee JY, Choi JA, Kwon SJ, Park JH, Park JH. Toll-like receptor 2 promotes bacterial clearance during the initial stage of pulmonary infection with Acinetobacter baumannii. Mol Med Rep. 2014 Apr;9(4):1410–1414. https://doi.org/10.3892/mmr.2014.1966
- Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoorn L, Tshimbalanga N, Akira S, van der Poll T. Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit Care Med. 2006 Jan 1;173(1):122–129. https://doi.org/10.1164/rccm.200505-730OC
- La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol. 2006 Mar;44(3):827–832. https://doi.org/10.1128/JCM.44.3.827-832.2006
- Lau GW, Ran H, Kong F, Hassett DJ, Mavrodi D. Pseudomonas aeruginosa pyocyanin is critical for lung infection in mice. Infect Immun. 2004 Jul;72(7):4275–4278. https://doi.org/10.1128/IAI.72.7.4275-4278.2004
- Lee HH, Aslanyan L, Vidyasagar A, Brennan MB, Tauber MS, Carrillo-Sepulveda MA, Dores MR, Rigel NW, Martinez LR. Depletion of alveolar macrophages increases pulmonary neutrophil infiltration, tissue damage, and sepsis in a murine model of Acinetobacter baumannii pneumonia. Infect Immun. 2020 Jun 22; 88(7):e00128-20. https://doi.org/10.1128/IAI.00128-20
- Luna BM, Yan J, Reyna Z, Moon E, Nielsen TB, Reza H, Lu P, Bonomo R, Louie A, Drusano G, et al. Natural history of Acinetobacter baumannii infection in mice. PLoS One. 2019 Jul 18;14(7): e0219824. https://doi.org/10.1371/journal.pone.0219824
- Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review. Front Microbiol. 2019 Apr 1;10:539. https://doi.org/10.3389/fmicb.2019.00539
- Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008 Mar 20;358(12):1271–81. https://doi.org/10.1056/NEJMra070741
- Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008 Jul;21(3): 538–582. https://doi.org/10.1128/CMR.00058-07
- Qiu H, KuoLee R, Harris G, Chen W. High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect. 2009a Oct;11(12):946–955. https://doi.org/10.1016/j.micinf.2009.06.003
- Qiu H, Kuolee R, Harris G, Chen W. Role of NADPH phagocyte oxidase in host defense against acute respiratory Acinetobacter baumannii infection in mice. Infect Immun. 2009b Mar;77(3):1015–1021. https://doi.org/10.1128/IAI.01029-08
- Qiu H, KuoLee R, Harris G, Van Rooijen N, Patel GB, Van Rooijen N, Patel GB, Chen W. Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PLoS One. 2012;7(6):e40019. https://doi.org/10.1371/journal.pone.0040019
- Sato Y, Unno Y, Miyazaki C, Ubagai T, Ono Y. Multidrug-resistant Acinetobacter baumannii resists reactive oxygen species and survives in macrophages. Sci Rep. 2019 Nov 25;9(1):17462. https://doi.org/10.1038/s41598-019-53846-3
- Uppalapati, SR., Sett A, Pathania, R. The outer membrane proteins OmpA, CarO, and OprD of Acinetobacter baumannii confer a two-pronged defense in facilitating its success as a potent human pathogen. Front Microbiol. 2020 Oct 6;11:589234. https://doi.org/10.3389/fmicb.2020.589234
- Usher LR, Lawson RA, Geary I, Taylor CJ, Bingle CD, Taylor GW, Whyte MK. Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection. J Immunol. 2002 Feb 15;168(4):1861–1868. https://doi.org/10.4049/jimmunol.168.4.1861
- Ushizawa H, Yahata Y, Endo T, Iwashima T, Misawa M, Sonobe M, Yamagishi T, Kamiya H, Nakashima K, Matsui T, et al. A epidemiological investigation of a nosocomial outbreak of multidrug-resistant Acinetobacter baumannii in a Critical Care Center in Japan, 2011–2012. Jpn J Infect Dis. 2016;69(2):143–148. https://doi.org/10.7883/yoken.JJID.2015.049
- van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun. 2007 Dec;75(12):5597–5608. https://doi.org/10.1128/IAI.00762-07
- Yong VF, Soh MM, Jaggi TK, Mac Aogáin M, Chotirmall SH. The microbial endocrinology of Pseudomonas aeruginosa: inflammatory and immune perspectives. Arch Immunol Ther Exp. 2018 Oct;66(5):329–339. https://doi.org/10.1007/s00005-018-0510-1
- Zeng X, Gu H, Cheng Y, Jia KR, Liu D, Yuan Y, Chen ZF, Peng LS, Zou QM, Shi Y. A lethal pneumonia model of Acinetobacter baumannii: an investigation in immunocompetent mice. lin Microbiol Infect. 2019 Apr;25(4):516.e1-516.e4. https://doi.org/10.1016/j.cmi.2018.12.020